ArticleCureus2025
Central Centrifugal Cicatricial Alopecia: A Survey of Treatment Practices Among Dermatology Residents and Attending Physicians.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Central centrifugal cicatricial alopecia (CCCA) is a type of primary scarring alopecia characterized by hair loss on the vertex of the scalp. While treatment often focuses on reducing inflammation, no established standard of care exists. Early diagnosis and intervention are critical, as advanced stages with permanent follicular scarring are challenging to treat. Our study aims to assess CCCA treatment practices and provider confidence among dermatology residents and attendings in an urban academic setting. We further compare these real-world practices with existing literature. Methods We conducted a cross-sectional survey study of the commonly prescribed/recommended treatments for CCCA in 31 residents and attending physicians at two dermatology programs. Of those, 26 indicated that they see patients with CCCA, comprising 17 residents and nine attending physicians. Results Overall, the most frequently utilized therapies for CCCA were topical corticosteroids (TCS) (n = 26), designated as first-line by 90.5% of users, topical minoxidil (n = 24), used first-line by 77.3%, and intralesional corticosteroids (n = 24), used first-line by 65% of users. Oral tetracyclines were used by only 56% (n = 14) of respondents. Discussion Our findings mostly align with the current recommendations in the literature, focusing on reducing inflammation with topical and intralesional corticosteroids. Interestingly, topical minoxidil was used first-line by most respondents, possibly reflecting its greater accessibility to our patient population. The discrepancies in our findings may be reflective of variability in provider comfort in CCCA management, concern for side effects of systemic treatments, and presentations of later, "burnt-out" stages of CCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.